Press Release Summary: Intas Biopharmaceuticals Limited, an Ahmedabad-based biopharmaceutical company, has chalked elaborate marketing plans for its global and domestic operations for this fiscal. The company engaged in R&D, Manufacturing and Marketing of biotech drugs, signed supply agreement in Africa to consolidate its position in "Middle East North Africa" region. Initially, the company is looking to supply and market three products - NeukineŽ, ErykineŽ and IntalfaŽ and at a later stage, it can expand its operations in the region. With this agreement in place, Intas Biopharmaceuticals, now has its reach in Morocco, Algeria, West Africa (Ivory Coast, Senegal, Mali, Cameroon), Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates.
Press Release Body: Sharing the marketing plans for MENA region, Mr. Simon Daniel, Chief Executive (Marketing), said, "The supply agreement in Africa gives a strategic advantage to IBPL in strengthening its market position in MENA region and serves the goal of reaching new destinations. The technology strength of IBPL and market intelligence/distribution network of our local partner in Africa can be unified for providing the much-needed boost to establish business rapidly. We are looking forward to more agreements with leading international pharmaceutical/biotech companies in future to expand our market reach of products.
The epidemiological trends of MENA region combined with high population growth, the current socio economical situation along with the improvement of educational level are as many elements in favour, not only of a growing need for biotech products and services in the region in the near future, but also for an equitable access to such products and services."
With recently announced agreement in North America for NeukineŽ, IBPL's reach has extended to every continent and geographical region. This business deal brings together two companies, with complimentary strengths and niche expertise, which will help in launching the first GCSF generic in North America. After EU GMP certification, the entry into semi-regulated markets has become relatively easy for IBPL as the quality conscious Pharma/Biotech companies are assured of superior quality of products and services. Amongst regulated/semi-regulated markets, IBPL offers an edge over its competitors in terms of unique pricing, products, services and its marketing strategy. With unique capabilities of R&D, Manufacturing and Marketing, IBPL has significant presence in Europe, Asia-Pacific, Middle East, Russia & CIS, South and Central America and Africa.
Further elaborating on company's future prospects, Mr. Simon Daniel said, "IBPL is looking to consolidate its position in the Contract Research and Manufacturing Services (CRAMS) segment. The company has taken up CRAMS opportunity as a focus area with tremendous potential and are preparing to scale up the facilities. With respect to CRAMS, IBPL offers a unique business model for offshore clients from regulated/semi-regulated markets and has competitive advantage in terms of developing new biotech products, technology transfer and contract manufacturing at committed costs, quality and time to create a competitive advantage for the company. With growing business opportunities, IBPL will find itself in the best position to plan certain key initiatives in the coming financial year."
Speaking on IBPL's domestic operations, Mr. Daniel said, "In order to give impetus to IBPL's sales activities, the company plans to launch new sales division BRIDGE catering to Nephrology / Neurology therapeutic areas. IBPL is the only Indian biotech company to manufacture Pegylated GCSF and market it under the brand name NeupegT. The product offers treatment against toxicity caused due to chemotherapy in cancer patients. This USP has prompted the need for a special and dedicated sales division RELAY. IBPL has doubled its sales force to allow more focussed approach towards niche therapeutic areas of Oncology. Keeping in view the future product pipeline, increasing the sales force is an important step towards strengthening IBPL's presence in the domestic market."
Intas entered the Indian anti-cancer market in the year 1998 with the launch of Novatech division (oncology marketing division). Starting with a product basket of a few oncology products in 1999, today, IBPL can boast of one of the most comprehensive oncology product basket comprising of 26 products in different dosage forms (capsules, injections, tablets and pre-filled syringes).
2025
